---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-058172"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:16:49.671062+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q3 net loss $129.4M ($1.35/sh); SEQUOIA-HCM topline late Dec.

## Summary
- Net loss for Q3 2023 was $129.4M ($1.35/diluted share) vs $142.3M ($1.52) in Q3 2022.
- Cash, cash equivalents and investments totaled $554.7M at Sep 30, 2023; received $50M milestone from Royalty Pharma.
- Q3 revenue dropped to $0.4M from $2.5M YoY; nine-month revenue $5.9M vs $92.6M prior.
- Topline results from pivotal Phase 3 SEQUOIA-HCM (aficamten in obstructive HCM) expected late December.
- Submitted formal dispute resolution to FDA regarding omecamtiv mecarbil CRL; EMA responses submitted.

## SEC filing metadata
- accession: 0000950170-23-058172
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017023058172/0000950170-23-058172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017023058172/cytk-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-058172
- JSON: https://secwatch.observer/filing/0000950170-23-058172.json
- Plain text: https://secwatch.observer/filing/0000950170-23-058172.txt

## Key facts
- Earnings Releases
  CYTOKINETICS INC reported third quarter ended September 30, 2023 results: net income $129.4 million, EPS $1.35 per share.
  - Period: third quarter ended September 30, 2023
  - Net income: $129.4 million
  - EPS: $1.35 per share
  - Result: reported results
  source text: Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2023. Net loss for the third quarter was $129.4 million, or $1.35 per share, compared to net loss for the third quarter of 2022 of $142.3 million, or $1.52 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017023058172/0000950170-23-058172-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.